TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)
Title:
TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)
Author:
Agarwal, N. Azad, A.A. Fizazi, K. Mateo, J. Matsubara, N. Shore, N.D. Chakrabarti, J. Chen, H.-C. Lanzalone, S. Niyazov, A. Saad, F.
Appeared in:
European urology open science
Paging:
Volume 33 () nr. S3 pages S273
Year:
2021
Contents:
Publisher:
European Association of Urology. Published by Elsevier B.V.